Pricing Log in Create free account
Friday 6 November 2026 Export ENOV’s income statement to Excel — free account

Enovis Corporation

ENOV Healthcare Medical Devices

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.

Revenue
+1.79%
EPS
+100.6%
Free cash flow
+20.3%
Total debt
−7.45%

Quarter to September 2026, against a year earlier

27.05 1.57 −5.49%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
98.6×
Dividend yield
—
F-score
4/9
Altman Z
−0.34
Beneish M
−4.29
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.69
Sold, $m 0.05
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 4 — — 4 — — 3 — —
Sell 1 — — — — — — — — — — —
Insider Ownership 3.85%

Capital & Financial Ratios $m

Size
Market Cap 1,650.00
Revenue ttm 2,306.42
Net income ttm (526.52)
Free cash flow ttm 69.56
Net debt Q 1,245.22
Valuation
P/E 0.00
Forward P/E 98.60 (above 35: high)
Price / sales 0.72
Forward P/S Powerpack
Price / FCF 23.80
Price / book 1.11
Financial health
Current ratio Q 2.15 (at or above 1.5: strong)
Debt / equity Q 0.84
Interest coverage Q 0.44
Growth
Revenue growth Q +1.79% (above 0%: growing)
Operating income growth Q +100.60% (above 0%: growing)
EPS, this year +11.15%
EPS, next year A −3.63% (below 0%: weak)
Revenue, next year A +4.05%
EPS, past 5 yrs —
EPS, next 5 yrs A +5.44%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 2.1×; over the ten years it ranged from 0.8× in 2016 to 20.4× in 2021.
P/S against its own 10 years 16.46%
10-year low 10-year high
P/B against its own 10 years 63.18%
10-year low 10-year high
EV/Sales against its own 10 years 14.85%
10-year low 10-year high
EV/FCF against its own 10 years 60.14%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 36 48 36 13
Receivables 291 407 443 428
Inventory 469 547 584 620
Other 71 108 101 137
897 1,146 1,207 1,248
2023 2024 2025 Q'26
Payables 132 179 188 200
ST’ Debt — 20 35 35
Other — — — —
370 529 598 580

Compound Annual Growth %

10y 5y 3y
Sales (4.15%) 14.94% 12.88%
Cash Flow (3.30%) (6.37%) 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (7.51%) (16.10%) (24.38%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.83 Actual 0.90

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.67 0.75 Beat by 0.08
Q4 FY25 0.81 0.95 Beat by 0.14
Q1 FY26 0.82 0.89 Beat by 0.07
Q2 FY26 0.83 0.90 Beat by 0.07
Q3 FY26 0.76 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.15) (0.02) 0.06 — —
’25 (0.98) (0.64) (9.99) (9.10) (20.75)
’24 (1.32) (0.34) (0.58) (12.05) (14.93)
’23 (0.43) (0.18) (0.05) 0.05 (0.61)
’22 0.33 1.41 (1.23) (0.71) (0.25)
’21 0.39 0.54 0.48 (0.03) 1.38
’20 0.09 (0.18) 0.30 0.72 0.93
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 589 583 559 — —
’25 559 565 549 576 2,248
’24 516 525 505 561 2,108
’23 406 429 418 455 1,707
’22 375 395 384 409 1,563
’21 879 356 360 (169) 1,426
’20 816 620 806 (1,122) 1,121
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 24 75 71 — —
’25 (2) 48 83 89 217
’24 (36) 8 54 88 114
’23 7 28 31 68 135
’22 (14) (25) 19 (36) (56)
’21 84 78 97 96 356
’20 56 37 80 129 302
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) 31 35 — —
’25 (45) 3 29 32 20
’24 (73) (32) 2 35 (67)
’23 (23) (9) 47 30 45
’22 (36) (49) (1) (73) (159)
’21 60 61 68 70 259
’20 27 21 49 100 197
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 3,186 1,937 2,193 3,327 1,121 1,426 1,563 1,707 2,108 2,248 2,306 (3.8%) 2,339 2,454 2,569 +4.5%
Gross margin, % 31.15 34.67 33.26 42.11 53.86 54.53 55.62 58.04 56.02 59.84 61.31 +28.7 pt
EBT 207 49 92 50 (119) (122) (2) (67) (823) (1,159) (502) n/m
EBT margin, % 6.48 2.51 4.21 1.52 (10.62) (8.54) (0.13) (3.93) (39.05) (51.57) (21.76) (58.1) pt
Net income 145 170 154 (517) 46 76 (12) (33) (825) (1,184) (527) n/m
Per share, $
Per share, $ Revenue 77.76 47.17 54.70 73.56 24.58 27.89 28.91 31.33 38.13 39.39 39.43 (7.3%)
Earnings 3.12 3.69 3.48 (11.67) 0.93 1.41 (0.25) (0.61) (14.93) (20.75) (9.21) n/m
Cash flow 6.03 5.33 5.65 2.89 6.62 6.96 (1.03) 2.48 2.05 3.81 4.43 (5.0%)
Capex (1.37) (1.16) (0.87) (2.60) (2.31) (1.90) (1.90) (1.65) (3.27) (3.46) (3.24) +10.9%
Free cash flow 4.66 4.17 4.78 0.29 4.31 5.06 (2.93) 0.83 (1.22) 0.35 1.19 (25.0%)
Book value 75.51 90.75 86.72 77.15 78.70 91.15 63.81 62.77 46.39 26.14 25.57 (11.1%)
Shares, m 41 41 40 45 46 51 54 54 55 57 58 +3.8%
Valuation, ×
Valuation, × P/E 35.48 32.64 17.86 0.00 123.34 95.76 0.00 0.00 0.00 0.00 0.00 30.5
P/S 1.42 2.53 1.15 1.48 4.67 4.95 1.88 1.77 1.15 0.68 0.72 2.2
P/B 1.47 1.32 0.72 1.41 1.46 1.51 0.85 0.88 0.95 1.02 1.11 1.2
EV/Sales 1.76 2.87 1.66 2.15 6.57 5.93 2.03 2.03 1.76 1.24 1.26 2.8
EV/FCF 29.42 32.45 18.97 535.69 37.44 32.67 (20.03) 76.59 (55.16) 139.62 41.70 82.8
Cash, $m
Cash, $m Operating cash flow 247 219 226 131 302 356 (56) 135 114 217 259 (1.4%)
Capex (56) (48) (35) (118) (105) (97) (103) (90) (181) (197) (189) +15.0%
Free cash flow 191 171 192 13 197 259 (159) 45 (67) 20 70 (22.2%)
Balance, $m
Balance, $m Working capital 679 972 759 547 550 1,280 230 527 617 609 668 (1.2%)
Net debt 1,083 649 1,120 2,202 2,134 1,406 235 430 1,281 1,260 1,245 +1.7%
Shareholders’ equity 3,093 3,727 3,477 3,490 3,588 4,661 3,450 3,421 2,564 1,492 1,496 (7.8%)
Returns, %
Returns, % ROA 1.96 2.32 2.10 (7.54) 0.58 0.90 (0.21) (0.76) (17.89) (27.69) (12.91) (29.6) pt
ROIC 3.54 1.94 2.06 2.24 (0.72) (0.65) (1.21) (1.07) (12.61) (25.53) (10.83) (29.1) pt
ROE 4.04 4.43 3.89 (15.15) 1.20 1.74 (0.33) (0.97) (27.59) (58.40) (29.97) (62.4) pt
People
People Employees 13,000 14,300 15,500 15,000 15,400 16,200 6,800 6,550 7,367 7,802 — (5.5%)
Revenue/emp, $m 0.25 0.14 0.14 0.22 0.07 0.09 0.23 0.26 0.29 0.29 — +1.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Enovis Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ENOV Enovis Corporation $1.7B — (loss-making) 98.6× +1.79% (above 0%: growing) n/m +20.30% (above 0%: growing) 60.83% 0.60%
NVCR NovoCure Limited $1.6B — (loss-making) — (loss-making) +15.67% (above 0%: growing) n/m +5.54% (above 0%: growing) 76.98% (3.19%) Compare
CNMD CONMED Corporation $1.6B 21.7× 11.7× −0.70% (below 0%: shrinking) +635.00% (above 0%: growing) −3.65% (below 0%: shrinking) 56.37% 11.07% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
TNDM Tandem Diabetes Care, Inc. $1.3B — (loss-making) — (loss-making) +13.82% (above 0%: growing) n/m −231.98% (below 0%: shrinking) 56.55% (0.84%) Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47% Compare
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60% Compare
Median of peers $1.2B — 26.0× +11.94% — −2.61% 60.29% 0.32%

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 6 April 2026

Ownership

Directors and executive officers, together 2.90%
BlackRock, Inc. 14.90%
American Century Investment Management, Inc. 8.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Enovis Corporation (ENOV) Latest News

5 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · StockStory
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

24 Oct

Impact 4 · · Simply Wall St.

23 Oct

Impact 3 · · StockStory

22 Oct

Impact 3 · · GlobeNewswire

10 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

28 Sep

Impact 3 · · StockStory

22 Sep

Impact 3 · · PR Newswire

4 Sep

Impact 3 ·

3 Sep

Impact 3 ·

2 Sep

Impact 4 ·
Impact 4 · · medtechdive.com

1 Sep

Impact 4 · · MarketBeat
Impact 4 ·
Impact 4 ·

8 Aug

Impact 3 · · MarketBeat transcript

6 Aug

Impact 3 ·
Impact 3 ·

30 Jul

Impact 3 ·

29 Jul

Impact 3 ·

13 Jul

Impact 3 ·

8 Jun

Impact 3 · · Simply Wall St.
Impact 3 · · GlobeNewswire

5 Jun

Impact 3 · · StockStory

4 Jun

Impact 3 · · Insider Monkey
stockrow.com/ENOV · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com